Cancer is caused by gain of function of proteins involved in proliferation and survival, and loss of function of proteins that regulate these processes (Hanahan and Weinberg, 2000). Strategies for treating cancer generally involve development of small molecules that block hyperactive enzymes, or take advantage of abnormal expression of protein targets on the surface of cancer cells. Developing therapies based on loss of function of tumor suppressors presents novel challenges. Loss of the protein phosphates PTEN and loss of the G1/S checkpoint protein pRB occurs frequently in cancer, and offers a number of potential drug targets. Loss of PTEN leads to hyperactivation of downstream enzymes such as AKT and mTOR (McCormick, 2004) whereas loss of pRB leads to hyper-activation of the transcription factor E2F, and increased expression of numerous potential targets, some of which have already been exploited for cancer therapy (dihydrofolate reductase and thymidylate synthase, for example, are the targets of methotrexate and 5-fluorouracil, respectively). Loss of p53, on the other hand, does not appear to offer any direct targets for intervention: in contrast to PTEN and pRB, p53 is a positive regulatory protein, whose targets are obviously lost rather than hyper-activated in cancer cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anders M., Christian C., McMahon M., McCormick F., Korn W.M. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 2003. 63: 2088-2095.
Babiss L.E., Ginsberg H.S., Darnell J.E. Jr. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol Cell Biol. 1985. 5: 2552-2558.
Bates S., Phillips A.C., Clark P.A., Stott F., Peters G., Ludwig R.L., Vousden K.H. p14ARF links the tumour suppressors RB and p53. Nature. 1998. 395: 124-125.
Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996. 274: 373-376.
Dobner T., Horikoshi N., Rubenwolf S., Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 1996. 272: 1470-1473.
Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 2000. 100: 57-70.
Harada J.N., Berk A.J. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol. 1999. 73: 5333-5344.
Harada J.N., Shevchenko A., Pallas D.C., and Berk A.J. Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol. 2002. 76: 9194-9206.
Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997. 3: 639-645.
Kao C.C., Yew P.R., Berk A.J.. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology. 1990. 179: 806-814.
Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., Gore M., Ironside J., MacDougall R.H., Heise C., Randlev B., Gillenwater A.M., Bruso P., Kaye S.B., Hong W.K., Kirn D.H. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [see comments]. Nat Med. 2000. 6: 879-885.
Lomax M., Frie M.. Polyoma virus disrupts ARF signaling to p53. Oncogene. 2001. 20: 4951-4960.
McCormick F. ONYX-015 selectivity and the p14ARF pathway. Oncogene. 2000. 19: 6670-6672.
McCormick F. Cancer gene therapy: fringe or cutting edge?. Nat Rev Cancer. 2001. 1: 130-141.
McCormick F. Cancer: survival pathways meet their end. Nature. 2004. 428: 267-269.
McCormick F., Harlow, E. Association of a murine 53,000-dalton phosphoprotein with simian virus 40 large-T antigen in transformed cells. J Virol. 1980. 34: 213-224.
Milner J., McCormick F. Lymphocyte stimulation: concanavalin A induces the expression of a 53K protein. Cell Biol Int Rep. 1980. 4: 663-667.
Nishizaki M., Fujiwara T., Tanida T., Hizuta A., Nishimori H., Tokino T., Nakamura Y., Bouvet M., Roth J.A., Tanaka N. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer. 1999. Res 5: 1015-1023.
Querido E., Blanchette P., Yan Q., Kamura T., Morrison M., Boivin D., Kaelin W.G., Conaway R.C., Conaway J.W., Branton P.E. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 2001. 15: 3104-3117.
Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., Randlev B., Heise C., Uprichard M., Hatfield M., Rome L., Rubin J., Kirn D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002. 62: 6070-6079.
Ries S.J., Brandts C.H., Chung A.S., Biederer C.H., Hann B.C., Lipner E.M., McCormick F., Korn W.M. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med. 2000. 6: 1128-1133.
Rothmann T., Hengstermann A., Whitaker N.J., Scheffner M. zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998. 72: 9470-9478.
Rudin C.M., Cohen E.E., Papadimitrakopoulou V.A., Silverman S. Jr., Recant W., El-Naggar A.K., Stenson K., Lippman S.M., Hong W.K., Vokes E.E. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003. 21: 4546-4552.
Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990. 63: 1129-1136.
Swisher S.G., Roth J.A. Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am. 2002. 11: 521-535.
Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A.. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004. 303: 844-848.
Yew P.R., Kao C.C., Berk, A.J. Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis. Virology. 1990. 179: 795-805.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer
About this chapter
Cite this chapter
McCormick, F. (2007). Novel Approaches to p53-Based Therapy: ONYX-015. In: Hainaut, P., Wiman, K.G. (eds) 25 Years of p53 Research. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-2922-6_19
Download citation
DOI: https://doi.org/10.1007/978-1-4020-2922-6_19
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-2920-2
Online ISBN: 978-1-4020-2922-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)